# Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

> **NCT06374888** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Convalife (Shanghai) Co., Ltd.** · enrollment: 28 (estimated)

## Conditions studied

- Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis

## Interventions

- **DRUG:** Neratinib maleate in combination with capecitabine

## Key facts

- **NCT ID:** NCT06374888
- **Lead sponsor:** Convalife (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-09-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374888, "Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06374888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*